Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival.
暂无分享,去创建一个
Mark E. Williams | J. Lazarus | E. Lacson | N. Ofsthun | M. E. Williams | E. Lacson | M. Teng | M Teng | J M Lazarus | M E Williams | E Lacson | N Ofsthun
[1] A. Sehgal,et al. The provision and outcomes of diabetic care of hemodialysis patients. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[2] R. Gleason,et al. Reproducibility of hemoglobin AIc and sensitivity to various degrees of glucose intolerance. , 1979, Annals of internal medicine.
[3] R. Holman,et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.
[4] K. Svärdsudd,et al. Long-Term Glycemic Control Relates to Mortality in Type II Diabetes , 1995, Diabetes Care.
[5] Charles M Peterson,et al. Tests of glycemia in diabetes. , 1995, Diabetes care.
[6] N. Wareham,et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) , 2001, BMJ : British Medical Journal.
[7] A. Levey,et al. Cardiovascular disease and chronic renal disease: a new paradigm. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[8] S. Saydah,et al. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. , 2004, JAMA.
[9] M. Laakso,et al. NIDDM and Its Metabolic Control Predict Coronary Heart Disease in Elderly Subjects , 1994, Diabetes.
[10] C. Marenah,et al. Glycated Proteins as Indices of Glycaemic Control in Diabetic Patients with Chronic Renal Failure , 1996, Diabetic medicine : a journal of the British Diabetic Association.
[11] D. Singer,et al. Tracking of glycated hemoglobin in the original cohort of the Framingham Heart Study. , 1996, Journal of clinical epidemiology.
[12] M. Akmal. Hemodialysis in diabetic patients. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[13] S. Bowlin,et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. , 2004, Diabetes care.
[14] M. Hanefeld,et al. Postprandial glucose regulation and diabetic complications. , 2004, Archives of internal medicine.
[15] E G Lowrie,et al. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[16] D. Goldstein,et al. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. , 2002, Diabetes care.
[17] G. Chertow,et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. , 2004, Journal of the American Society of Nephrology : JASN.
[18] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[19] E. Feskens,et al. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.
[20] H Wedel,et al. Infarction : Long-Term Results From the Diabetes and Insulin-Glucose Infusion Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Glycometabolic State at Admission : Important Risk Marker of Mortality in , 1999 .
[21] M. Engelgau,et al. The Evolving Diabetes Burden in the United States , 2004, Annals of Internal Medicine.
[22] T. Shoji,et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. , 2001, Diabetes care.
[23] P. Diem,et al. [What you always wanted to know about HbA1c]. , 2000, Schweizerische medizinische Wochenschrift.
[24] P. Raskin,et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.
[25] K. Malmberg. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus , 1997, BMJ.
[26] D. Goldsmith,et al. Assessing glycemic control in patients with diabetes and end-stage renal failure. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[27] M. Hanefeld,et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up , 1996, Diabetologia.
[28] Neil R. Powe,et al. Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus , 2004, Annals of Internal Medicine.
[29] W. Cefalu,et al. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[30] E. Friedman,et al. Interdialytic weight gain correlates with glycosylated hemoglobin in diabetic hemodialysis patients. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[31] A. Agrawal,et al. Can glycohemoglobin be used to assess glycemic control in patients with chronic renal failure? , 2002, Clinical chemistry.
[32] E. Eschwège,et al. Evaluation of risk factors for development of complications in Type II diabetes in Europe , 2002, Diabetologia.
[33] M. Feinglos,et al. Emerging care for type 2 diabetes: using insulin to reach lower glycemic goals. , 2005, Cleveland Clinic journal of medicine.
[34] A. Folsom,et al. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. , 2005, Archives of internal medicine.
[35] C. Manske. Hyperglycemia and intensive glycemic control in diabetic patients with chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[36] L. Sheiner,et al. A pharmacodynamic model of erythropoietin therapy for uremic anemia , 1992, Clinical pharmacology and therapeutics.
[37] G. Beck,et al. Glycosylated hemoglobin and mortality in patients with nondiabetic chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.
[38] T. Nakao,et al. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. , 1998, Internal medicine.
[39] A. Collins,et al. Chronic kidney disease and cardiovascular disease in the Medicare population. , 2003, Kidney international. Supplement.
[40] S. Haffner,et al. Effects of Diabetes and Level of Glycemia on All-Cause and Cardiovascular Mortality: The San Antonio Heart Study , 1998, Diabetes Care.
[41] M Hørder,et al. Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes mellitus. , 1990, The New England journal of medicine.
[42] H. Makino,et al. What is the best index of glycemic control in patients with diabetes mellitus on hemodialysis? , 1996, Nihon Jinzo Gakkai shi.
[43] R. Mak. Impact of End‐Stage Renal Disease and Dialysis on Glycemic Control , 2000, Seminars in dialysis.
[44] G. Biesenbach,et al. Long-Term Impact of Chronic Hemodialysis on Glycemic Control and Serum Lipids in Insulin-Treated Type 2-Diabetic Patients , 2005, Renal failure.
[45] G. Murata,et al. The Relationship Between Glycemic Control and Morbidity and Mortality for Diabetics on Dialysis , 1993, ASAIO journal.
[46] Winfried März,et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005 .
[47] P. Conlin,et al. Development of evidence-based clinical practice guidelines for diabetes: the Department of Veterans Affairs/Department of Defense guidelines initiative. , 2004, Diabetes care.